{"name":"Nabriva Therapeutics AG","slug":"nabriva-therapeutics-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":36935000,"revenueGrowth":27.8,"grossMargin":0,"rdSpend":14263000,"netIncome":-57185000,"cash":31765000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BC-3781","genericName":"BC-3781","slug":"bc-3781","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BC-3781","genericName":"BC-3781","slug":"bc-3781","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPajd3anJVTFAtbUlBOVU5OHhjYXVmWlRzNGZxOGFTUGZQNHNYYUFWWm9WOXlOSm96WW1yRkF4N2dXYW1LemxnT25HR2tCeFB4VDY5dWM0SmE3TzBlTkVSNTc5RWxMVHVXZWpNZGxjeDZSSTZkZ0kzeTdCT2Rmc0xhMG9ZUmpoSThEQmxIeS1xb3VOQVF0cm1fNWRVMDQ5SGxwZUJWaFZsaG9LRUpFUGdHTkVUOXc4N2Z2TFI0RVkydw?oc=5","date":"2025-08-19","type":"regulatory","source":"Pharmaceutical Technology","summary":"FDA approves Xenleta for community-acquired bacterial Pneumonia - Pharmaceutical Technology","headline":"FDA approves Xenleta for community-acquired bacterial Pneumonia","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxNc1FqUml6SzFDZHRSZDVrOUZzSWRtejNpa0JhSldBd192Um1CeWNGMEVZVm1RUzMwTGZHQV81bmRRM3RiSDhxaDJZWnpCYm15T1MyRGNtOGZZNUw2eHdfWEZ1V3duc1hYZGJEQVpIWXBTa2VTSEIzMlJfMGFJYjJlNmd4dkktNlFBQlNiU2FoUkpDeTkwVVJQTDJMRWt0aEVMLWxyRk1Pcw?oc=5","date":"2024-12-12","type":"pipeline","source":"World Pharmaceutical Frontiers","summary":"Meitheal secures exclusive commercial rights to Xenleta in US - World Pharmaceutical Frontiers","headline":"Meitheal secures exclusive commercial rights to Xenleta in US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxNaXpvTGNmVjNjRGVlRVhLcHN3ZVZxbnNaVm5TNXFlS280VGVpZnN6aDQyT0lOcWxxRDluTk5WWVlUWnNzNl9BbnU2UmFyUllONFZrdndfdmFIR09LWi1YNnREY0xINWJaWFZnNGwzZHlOSGdEN2JLNG5sWEo5Vk5wLTFFb3Y0ZFZoSDNEaVAzUjl1a2FfVnRwQ2hmOEN2Z19CUWFwLXg0eTJoVENUZkx3LWZSbHQ2WFc1RjM0NmI1ZXJXODg5QW9tSzlQUTBpUlE4M2NGd08xX0lUSU1EcFVZNjF0Wk1BVWxjb2NMcU1mQkE?oc=5","date":"2024-10-23","type":"pipeline","source":"GlobeNewswire","summary":"Antibiotics Market Size to Surpass USD 65.23 Billion by 2032, with 3.70% CAGR – SNS Insider - GlobeNewswire","headline":"Antibiotics Market Size to Surpass USD 65.23 Billion by 2032, with 3.70% CAGR – SNS Insider","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNVGZLUUFtVzg2MU12MUE5SGU5NzJMN3NEWTZ6QWN4UXFrTkYyTTY3Yy1fVlVqeUxRV2ZUMWt2eWctc3h1d1ZRV1pxM2Q5S19vRUZsX2I0S0d6UkYtdlNkcTFHY3BUQjdUdjVtRXZicGRCUkRMczVTbVRTMXpnSnhBWFBHWl82QQ?oc=5","date":"2024-07-19","type":"deal","source":"Pharmaceutical Technology","summary":"Meitheal acquires rights to CONTEPO from Nabriva - Pharmaceutical Technology","headline":"Meitheal acquires rights to CONTEPO from Nabriva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxOcGlSMXU1M2JiOFJfbktzT0s4ZF85WGxOS0VuWkhodzVXZjFxelFmTFlaSk51YXN2NTZQT2FWamFWYTExTUtxcUJVYjhTaGtSbjlDUjU2UEtHbTBKZjV1b19LNnRrVkVKVTZyaGY2aVp5UmF5NGZfWlNhR0FNTS12bG5hdkx4VW9jcXJmS1NSNXAzQUR1X2s2cXNUQjRpd09PMzdtWThYY0pYRGxJQzVhc3F5TzdIUXhZdExCdHlwQjBYNUtCbnJzLURoTjcwWGduWHU1Qlg0d2xwR3RvYldjZUl2MA?oc=5","date":"2023-12-28","type":"pipeline","source":"PharmiWeb.com","summary":"Global Complicated Urinary Tract Infections Treatment Industry size is set to experience a 5.76% CAG - PharmiWeb.com","headline":"Global Complicated Urinary Tract Infections Treatment Industry size is set to experience a 5.76% CAG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOemsxU09pMmpzYXhPX2pzLXBLTEVPV2Q3b1BzRGhJekduQmtEX0x3S0Y0bktjNncteXExYzJON1lrN1VudGZLNndsQzV0T3RCaXczYVN3UWNrbHdoLXZQeGwtNEMtUzdac19CeXdsb0dNU3NBRzJwRmpLVTc2QkRZQmhIQU43c0JKX1l1d21ScGFURXFVVDFz?oc=5","date":"2023-11-10","type":"regulatory","source":"respiratory-therapy.com","summary":"New Drug to Treat Community-Acquired Pneumonia Fast Tracked by FDA - respiratory-therapy.com","headline":"New Drug to Treat Community-Acquired Pneumonia Fast Tracked by FDA - respiratory","sentiment":"neutral"},{"date":"2023-10-19","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2023-07-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-07-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-07-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-06-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxNd2x0VWstOWhIYWQ5RHpINEswVGRka3RZVEtSZnBSZFg2YTJSaF91QUdka1Zna3J1TjRhX2pqSHZRMkhMUzlWREtMZWpUbWpST2w1R2NiWTR2bXFHbHc1RThLQ2d1dW8tcFBQVGlmRjhDdWVOX3VSV3RzbkZIUDViR0FuMnZ4Njg3R2wyQ0JoUW95QTNYNjBNYWFVSENoajJwTWI0bVV5T2xQQjhlZ3I1bldoeW9BTnM5eWFGOEpRVmlCdHd6MWsyRm5WbFRTVmFQWlJ2QUV3V0dBYTBBbWU1ZmJWUnlVZ24zdjcxX3hyaw?oc=5","date":"2023-05-30","type":"pipeline","source":"European Medical Journal","summary":"Clostridioides difficile Infection: Targeting an Unwelcome and Persistent Threat - European Medical Journal","headline":"Clostridioides difficile Infection: Targeting an Unwelcome and Persistent Threat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQLWlxTWlPU2Q2MFJyc1JUMDM4NElaZm9jZTJIRWxuU1k5eHdpd2tkTnZ2d0tlWmhfT2tzb3hJQTI4OUFXUno1cG9YT3I0MjNnQ2IzZ253Zkx2RER1VE9POGx1ekI1NUVuaHJMdEU5TUFUNUU1aUNMSklPQmJCNUotSXhkc1ZvTDNaeGdGeWVKMFJ4M3JWZFNCaQ?oc=5","date":"2023-01-12","type":"pipeline","source":"cen.acs.org","summary":"Antibiotic developer Nabriva to wind down - cen.acs.org","headline":"Antibiotic developer Nabriva to wind down","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE4yRGtmOEh1c0xYYXF1TkxBZW9UMnJkZWhaR3ZqU25DVmJCd0RJOXJBbkxyUW9fM3JFSGVUM2ZSNmN6QjJOQ0lYMlBzTkoyQVozOWZqc1IzcDNTSXFxWDhTVmln?oc=5","date":"2022-02-09","type":"pipeline","source":"Pharmaceutical Executive","summary":"Ethics of Antibiotics - Pharmaceutical Executive","headline":"Ethics of Antibiotics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNd0U2ckUzd0M5dzd5WVJ6UDVENV9hLWVjS3NwMUJ5Q29JX19scTYtZldrMjRxWmpBWi1TU2J6SGJoMUNlN0o0RTloUzZWRDYyWUloX1BPbEJJcWI5SlhYZUFkYkNyMUVCZzFzNS00QzBnRVQtekFkRmUxQmNSMDRuak5ZV1poUnl0Y3c?oc=5","date":"2018-07-24","type":"pipeline","source":"Pharmaceutical Technology","summary":"Nabriva Therapeutics snaps up Zavante for its market-ready antibiotic - Pharmaceutical Technology","headline":"Nabriva Therapeutics snaps up Zavante for its market-ready antibiotic","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":36935000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":36935000,"period":"2022-12-31"},{"value":28895000,"period":"2021-12-31"},{"value":28895000,"period":"2021-12-31"},{"value":5027000,"period":"2020-12-31"},{"value":5027000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":14263000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-57185000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":31765000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}